Elebrato Ellipta is a medicine used to relieve the symptoms of moderate to severe chronic obstructive pulmonary disease (COPD). COPD is a long\-term disease in which the airways and air sacs inside the lungs become damaged or blocked, leading to difficulty breathing. Elebrato Ellipta is used in adults whose disease is not controlled well enough with a combination of inhaled medicines consisting of a long\-acting beta\-2 agonist plus either a corticosteroid or a long\-acting muscarinic antagonist. Long\-acting beta\-2 agonists widen the airways; corticosteroids reduce inflammation in the airways and lungs; and muscarinic receptor antagonists cause the muscles of the airways to relax. Elebrato Ellipta is used for maintenance (regular) treatment on a daily basis. It contains the active substances fluticasone furoate, umeclidinium bromide and vilanterol.
Therapeutic Indication
Elebrato Ellipta is indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid and a long\-acting ?2\-agonist.
Therapeutic Area (MeSH)
ATC Code
R03AL08
ATC Item
N/A
Pharmacotherapeutic Group
Drugs for obstructive airway diseases
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| fluticasone furoate | N/A | fluticasone furoate |
| umeclidinium bromide | N/A | umeclidinium bromide |
| vilanterol trifenatate | N/A | vilanterol trifenatate |
EMA Name
Elebrato Ellipta
Medicine Name
Elebrato Ellipta
Aliases
N/ANo risk management plan link.
